Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 112
Appendix D Workshop Agenda NATIONAL ACADEMY OF SCIENCES INSTITUTE OF MEDICINE FORUM ON EMERGING INFECTIONS "Antimicrobial Resistance, Surveillance, and Response" 2101 Constitution Avenue, N.W., Washington, D.C. July 30-31, 1997 WEDNESDAY, July 30th 9:00 WELCOME AND INTRODUCTION Joshua Lederberg, Forum Chairman 9:15 WHY ARE WE HERE? A FIRST LOOK AT THE COSTS OF ANTIMICROBIAL RESISTANCE Robert Rubin, The Lewin Group 9:30 TRACKING THE PROBLEM: APPROACHES TO SURVEILLANCE AND WHAT IS NEEDED An Overview David Bell, CDC The Global Perspective David Heymann, WHO A National Model Donald Low, Canada A Network for Research Karl Kristinsson, CEM/NET A U.S. State Perspective Michael Osterholm, Minnesota Department of Health
OCR for page 113
10 45 INTEGRATING PRIVATE- AND PUBLIC-SECTOR SURVEILLANCE: WHAT IS HAPPENING AND WHAT IS NEEDED Rosamund Williams, WHO Renu Gupta, Bristol-Myers Squibb Laurence McCarthy, MRL Pharmaceutical Services 11:30 SURVEILLANCE AND THE LABORATORY: WHAT ARE THE ISSUES? Fred Tenover, CDC 11:45 HOW CAN THE SCIENCE HELP? Implications of Mapping the Genome Craig Venter, Institute for Genomic Research Molecular Detection of Genes Associated with Antimicrobial Resistance David Relman, Stanford University 12:30 LUNCH 1:30 HOW CAN THE SCIENCE HELP? (continued) High-Density Oligonucleotide Arrays Tom Gingeras, Affymetrix Applications of Genomics/Bioinformatics to Development of Anti-Infectives George Miller, Schering-Plough Research Institute A Role for New Therapeutic Approaches in Combating Antimicrobial Resistance Mich Hein, EPIcyte Applications of Field Surveillance (U.S. and International) Thomas Quinn, Johns Hopkins University 2:30 SOURCES OF RESISTANCE AND NOTIONS OF RESPONSE Stuart Levy, Tufts University 2:45 ISSUES OF JUDICIOUS ANTIBIOTIC USE Mitchell Cohen, CDC 3:00 ISSUES IN AND STRATEGIES FOR CLINICAL USE OF ANTIMICROBIALS Michael Marcy, Kaiser Permanente
OCR for page 114
3:15 BREAK 3:30 RESISTANCE AND FOOD PRODUCTION: WHAT ISSUES, WHAT NEEDS? Concerns and Perspectives from Producers Paul Sundberg, National Pork Producers Council Salmonella DT104 on the Farm John Gay, Washington State University Concerns and Perspectives from the U.S. Department of Agriculture Bob Buchanan, USDA/ARS/ERRC Kaye Wachsmuth, USDA/FSI Concerns and Perspectives from the U.S. Environmental Protection Agency Mark Wilhite, EPA 4:45 DISCUSSION 5:30 ADJOURN THURSDAY, JULY 31 8:30 OTHER CONCERNS AND MECHANISMS OF RESPONSE Legal Issues Arising from Development of Antimicrobial Resistance David Fidler, University of Indiana Expired Patents and the Potential of Existing Compounds* Discussants: Gerald Mossinghoff, George Washington School of Law Vincent Ahonkhai, SmithKline Beecham Restricted Distribution and the Market** General Discussion with FDA participants as resources * Incentives: Developing Technologies for Emerging Infections." They were sufficiently provocative for us to feel that they merited further discussion to see what, if any, potential they might hold for stimulating new R&D and, in particular, dealing with antimicrobial resistance. ** Please note that although the FDA is formally listed only here, several FDA experts in specific fields were present to comment and answer questions.
OCR for page 115
Orphan Drug Act Update: Looking Through the Prism of Staphylococcus aureus in Japan* Discussants: Fred Tenover, CDC Mark Goldberger, FDA 10:00 GENERAL DISCUSSION: REVISITING YESTERDAY'S TOPICS AND EXTRACTING TAKEAWAY LESSONS, ISSUES, AND NEXT STEPS 11:00 ADJOURNMENT
Representative terms from entire chapter: